2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …

E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the …

K Zeppenfeld, J Tfelt-Hansen, M De Riva… - European heart …, 2022 - academic.oup.com
4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the clinical genome resource framework

CA James, JDH Jongbloed… - Circulation: Genomic …, 2021 - Am Heart Assoc
Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited
disease characterized by ventricular arrhythmias and progressive ventricular dysfunction …

Evolving diagnostic criteria for arrhythmogenic cardiomyopathy

D Corrado, A Zorzi, A Cipriani, B Bauce… - Journal of the …, 2021 - Am Heart Assoc
Criteria for diagnosis of arrhythmogenic cardiomyopathy (ACM) were first proposed in 1994
and revised in 2010 by a Task Force. Although the Task Force criteria demonstrated a good …

Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator

A Protonotarios, R Bariani, C Cappelletto… - European heart …, 2022 - academic.oup.com
Aims To study the impact of genotype on the performance of the 2019 risk model for
arrhythmogenic right ventricular cardiomyopathy (ARVC). Methods and results The study …

Inflammation and immune response in arrhythmogenic cardiomyopathy: state-of-the-art review

B Asatryan, A Asimaki, AP Landstrom, MY Khanji… - Circulation, 2021 - Am Heart Assoc
Arrhythmogenic cardiomyopathy (ACM) is a primary disease of the myocardium,
predominantly caused by genetic defects in proteins of the cardiac intercalated disc …

European heart rhythm association (EHRA)/heart rhythm society (HRS)/Asia pacific heart rhythm society (APHRS)/latin American heart rhythm society (LAHRS) expert …

AAM Wilde, C Semsarian, MF Márquez, AS Shamloo… - Europace, 2022 - academic.oup.com
Purpose Genetic testing has advanced significantly since the publication of the 2011
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the …

Arrhythmogenic left ventricular cardiomyopathy

D Corrado, C Basso - Heart, 2022 - heart.bmj.com
Arrhythmogenic cardiomyopathy (ACM) is a genetic heart muscle disease characterised by
substitution of the ventricular myocardium by fibrofatty tissue. 1 The disease was originally …

[HTML][HTML] Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report

D Corrado, A Anastasakis, C Basso, B Bauce… - International Journal of …, 2024 - Elsevier
Arrhythmogenic cardiomyopathy (ACM) is a heart muscle disease characterized by
prominent “non-ischemic” myocardial scarring predisposing to ventricular electrical …

[HTML][HTML] Diagnosis and management of rare cardiomyopathies in adult and paediatric patients. A position paper of the Italian Society of Cardiology (SIC) and Italian …

G Limongelli, R Adorisio, C Baggio, B Bauce… - International journal of …, 2022 - Elsevier
Cardiomyopathies (CMPs) are myocardial diseases in which the heart muscle is structurally
and functionally abnormal in the absence of coronary artery disease, hypertension, valvular …